PT  - JOURNAL ARTICLE
AU  - Sheila Tiemi Nagamatsu
AU  - Robert H Pietrzak
AU  - Ke Xu
AU  - John H Krystal
AU  - Joel Gelernter
AU  - Janitza Liz Montalvo-Ortiz
TI  - Dissecting the Epigenomic Differences between Smoking and Nicotine Dependence in a Veteran Cohort
AID  - 10.1101/2021.09.24.21264038
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.09.24.21264038
4099  - http://medrxiv.org/content/early/2021/09/27/2021.09.24.21264038.short
4100  - http://medrxiv.org/content/early/2021/09/27/2021.09.24.21264038.full
AB  - Background Smoking is a serious public health issue linked to more than 8 million deaths per year worldwide. It also may lead to nicotine dependence (ND). Smoking can induce long-lasting epigenetic changes. Although epigenetic alterations related to tobacco smoke have been largely studied, few works have investigated ND and its interaction with smoking status (SS).Objective We investigated the peripheral epigenomic profile of SS and ND in a U.S. male veteran cohort.Methods DNA from saliva was collected from 1,135 European American (EA) male U.S. military veterans. DNAm was assessed using the Illumina Infinium Human MethylationEPIC BeadChip array. SS was evaluated as: current smokers (n=137; 12.1%) and non-current smokers (never and former smokers; n=998; 87.9%). ND was assessed using the Fagerström Test for Nicotine Dependence (FTND). EWAS and co-methylation analyses were conducted for SS and ND.Results A total of 450 and 22 genome-wide significant differentially methylated sites (DMS) were associated with SS and ND, respectively (fifteen overlapped sites). We identified 97 DMS (43 genes) in SS-EWAS previously reported in the literature, including AHRR, and F2RL3 genes (p-value range: 1.95×10−83 to 4.5×10−33). ND novel DMS mapped to NEUROG1, ANPEP, and SLC29A1. Co-methylation analysis identified 386 modules (11 SS-related and 19 ND-related). SS-related modules showed enrichment for alcoholism, chemokine signaling pathway, and neurogenesis; while ND-related modules were enriched for cellular adhesion, and nicotine addiction.Conclusions This study confirms previous findings and identifies novel and -potentially specific - epigenetic signatures for SS and ND in a sample of EA male veterans.Competing Interest StatementConsultant: Aptinyx, Inc.; Atai Life Sciences; AstraZeneca Pharmaceuticals; Biogen, Idec, MA; Biomedisyn Corporation; Bionomics, Limited (Australia); Boehringer Ingelheim International; Cadent Therapeutics, Inc.; Clexio Bioscience, Ltd.; COMPASS Pathways, Limited, United Kingdom; Concert Pharmaceuticals, Inc.; Epiodyne, Inc.; EpiVario, Inc.; Greenwich Biosciences, Inc.; Heptares Therapeutics, Limited (UK); Janssen Research & Development; Jazz Pharmaceuticals, Inc.; Otsuka America Pharmaceutical, Inc.; Perception Neuroscience Holdings, Inc.; Spring Care, Inc.; Sunovion Pharmaceuticals, Inc.; Takeda Industries; Taisho Pharmaceutical Co., Ltd Board of Directors: Freedom Biosciences, Inc. Scientific Advisory Board: Biohaven Pharmaceuticals; BioXcel Therapeutics, Inc. (Clinical Advisory Board); Cadent Therapeutics, Inc. (Clinical Advisory Board); Cerevel Therapeutics, LLC; EpiVario, Inc. Eisai, Inc.; Jazz Pharmaceuticals, Inc.; Lohocla Research Corporation; Novartis Pharmaceuticals Corporation; PsychoGenics, Inc.; RBNC Therapeutics, Inc.; Tempero Bio, Inc.; Terran Biosciences, Inc. Stock; Biohaven Pharmaceuticals; Sage Pharmaceuticals; Spring Care, Inc. Stock Options: Biohaven Pharmaceuticals Medical Sciences; EpiVario, Inc.; RBNC Therapeutics, Inc.; Terran Biosciences, Inc.; Tempero Bio, Inc. JFK Financial Disclosure (Income Greater than $10,000) Editorial Board: Editor, Biological Psychiatry Patents and Inventions: 1. Seibyl JP, Krystal JH, Charney DS. Dopamine and noradrenergic reuptake inhibitors in treatment of schizophrenia. US Patent #:5,447,948.September 5, 1995; 2. Vladimir, Coric, Krystal, John H, Sanacora, Gerard. Glutamate Modulating Agents in the Treatment of Mental Disorders. US Patent No. 8,778,979 B2 Patent Issue Date: July 15, 2014. US Patent Application No. 15/695,164: Filing Date: 09/05/2017; 3. Charney D, Krystal JH, Manji H, Matthew S, Zarate C., Intranasal Administration of Ketamine to Treat Depression United States Patent Number: 9592207, Issue date: 3/14/2017. Licensed to Janssen Research & Development; 4. Zarate, C, Charney, DS, Manji, HK, Mathew, Sanjay J, Krystal, JH, Yale University. Methods for Treating Suicidal Ideation, Patent Application No. 15/379,013 filed on December 14, 2016 by Yale University Office of Cooperative Research; 5. Arias A, Petrakis I, Krystal JH. Composition and methods to treat addiction. Provisional Use Patent Application no.61/973/961. April 2, 2014. Filed by Yale University Office of Cooperative Research.; 6. Chekroud, A., Gueorguieva, R., & Krystal, JH. Treatment Selection for Major Depressive Disorder [filing date 3rd June 2016, USPTO docket number Y0087.70116US00]. Provisional patent submission by Yale University; 7. Gihyun, Yoon, Petrakis I, Krystal JH. Compounds, Compositions and Methods for Treating or Preventing Depression and Other Diseases. U. S. Provisional Patent Application No. 62/444,552, filed on January10, 2017 by Yale University Office of Cooperative Research OCR 7088 US01; 8. Abdallah, C, Krystal, JH, Duman, R, Sanacora, G. Combination Therapy for Treating or Preventing Depression or Other Mood Diseases. U.S. Provisional Patent Application No. 62/719,935 filed on August 20, 2018 by Yale University Office of Cooperative Research OCR 7451 US01; 9. John Krystal, Godfrey Pearlson, Stephanie OMalley, Marc Potenza, Fabrizio Gasparini, Baltazar Gomez-Mancilla, Vincent Malaterre. Mavoglurant in treating gambling and gaming disorders. U.S. Provisional Patent Application No. 63/125,181filed on December 14, 2020 by Yale University Office of Cooperative Research OCR 8065 US00 No other co-author reports conflict of interest.Funding StatementThis work is supported by the Department of Veterans Affairs via 1IK2CX002095-01A1 (JLMO), NIDA R21DA050160 (JLMO), P50AA012870 (JHK), DA12890 (JG), VA MERIT I01CX001849 (JG), and the U.S. Department of Veterans Affairs National Center for Posttraumatic Stress Disorder.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Human Subjects Subcommittee of the Veterans Affairs (VA) Connecticut Healthcare System and VA Office of Research & Development and all participants provided informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSummary statistics are included in the supplementary material.SSsmoking statusNDnicotine dependenceEAEuropean AmericanDNAmDNA methylationGWSgenome-wide significantDMSdifferentially methylated sitesEWASepigenome-wide association studiesNHRVSNational Health and Resilience in Veterans StudyVAVeterans AffairsFTNDFagerström Test for Nicotine DependencePPIprotein-protein interaction analysisOERObserved/expected rate